These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 31074083)

  • 1. Vasohibin-2 plays an essential role in metastasis of pancreatic ductal adenocarcinoma.
    Iida-Norita R; Kawamura M; Suzuki Y; Hamada S; Masamune A; Furukawa T; Sato Y
    Cancer Sci; 2019 Jul; 110(7):2296-2308. PubMed ID: 31074083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of vasohibin-2 in pancreatic ductal adenocarcinoma promotes tumor progression and is associated with a poor clinical outcome.
    Kim JC; Kim KT; Park JT; Kim HJ; Sato Y; Kim HS
    Hepatogastroenterology; 2015; 62(138):251-6. PubMed ID: 25916042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic Premalignant Lesions Secrete Tissue Inhibitor of Metalloproteinases-1, Which Activates Hepatic Stellate Cells Via CD63 Signaling to Create a Premetastatic Niche in the Liver.
    Grünwald B; Harant V; Schaten S; Frühschütz M; Spallek R; Höchst B; Stutzer K; Berchtold S; Erkan M; Prokopchuk O; Martignoni M; Esposito I; Heikenwalder M; Gupta A; Siveke J; Saftig P; Knolle P; Wohlleber D; Krüger A
    Gastroenterology; 2016 Nov; 151(5):1011-1024.e7. PubMed ID: 27506299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasohibin 2 promotes malignant behaviors of pancreatic cancer cells by inducing epithelial-mesenchymal transition via Hedgehog signaling pathway.
    Zhang Y; Xue X; Zhao X; Qin L; Shen Y; Dou H; Sun J; Wang T; Yang DQ
    Cancer Med; 2018 Nov; 7(11):5567-5576. PubMed ID: 30318866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasohibin-2-Targeting Therapies for the Treatment of Pancreatic Ductal Adenocarcinoma.
    Suzuki Y; Sato Y
    Tohoku J Exp Med; 2024 Mar; 262(3):163-171. PubMed ID: 38220168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall survival of pancreatic ductal adenocarcinoma is doubled by
    Lee JS; Lee H; Woo SM; Jang H; Jeon Y; Kim HY; Song J; Lee WJ; Hong EK; Park SJ; Han SS; Kim SY
    Theranostics; 2021; 11(7):3472-3488. PubMed ID: 33537098
    [No Abstract]   [Full Text] [Related]  

  • 7. Knockout of vasohibin-2 reduces tubulin carboxypeptidase activity and increases paclitaxel sensitivity in ovarian cancer.
    Koyanagi T; Saga Y; Takahashi Y; Tamura K; Yoshiba T; Takahashi S; Taneichi A; Takei Y; Urabe M; Mizukami H; Fujiwara H
    Cancer Med; 2021 Apr; 10(8):2732-2739. PubMed ID: 33710778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis.
    Takahashi Y; Koyanagi T; Suzuki Y; Saga Y; Kanomata N; Moriya T; Suzuki M; Sato Y
    Mol Cancer Res; 2012 Sep; 10(9):1135-46. PubMed ID: 22826464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant upregulation of KLK10 promotes metastasis via enhancement of EMT and FAK/SRC/ERK axis in PDAC.
    Cao XY; Zhang XX; Yang MW; Hu LP; Jiang SH; Tian GA; Zhu LL; Li Q; Sun YW; Zhang ZG
    Biochem Biophys Res Commun; 2018 May; 499(3):584-593. PubMed ID: 29621546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of HIF1A From Pancreatic Cancer Cells Increases Expression of PPP1R1B and Degradation of p53 to Promote Invasion and Metastasis.
    Tiwari A; Tashiro K; Dixit A; Soni A; Vogel K; Hall B; Shafqat I; Slaughter J; Param N; Le A; Saunders E; Paithane U; Garcia G; Campos AR; Zettervall J; Carlson M; Starr TK; Marahrens Y; Deshpande AJ; Commisso C; Provenzano PP; Bagchi A
    Gastroenterology; 2020 Nov; 159(5):1882-1897.e5. PubMed ID: 32768595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-β signaling pathway.
    Yin Z; Ma T; Huang B; Lin L; Zhou Y; Yan J; Zou Y; Chen S
    J Exp Clin Cancer Res; 2019 Jul; 38(1):310. PubMed ID: 31307515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma.
    Lakshmanan I; Marimuthu S; Chaudhary S; Seshacharyulu P; Rachagani S; Muniyan S; Chirravuri-Venkata R; Atri P; Rauth S; Nimmakayala RK; Siddiqui JA; Gautam SK; Shah A; Natarajan G; Parte S; Bhyravbhatla N; Mallya K; Haridas D; Talmon GA; Smith LM; Kumar S; Ganti AK; Jain M; Ponnusamy MP; Batra SK
    Oncogene; 2022 Nov; 41(48):5147-5159. PubMed ID: 36271032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCR4 in Tumor Epithelial Cells Mediates Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma.
    Morita T; Kodama Y; Shiokawa M; Kuriyama K; Marui S; Kuwada T; Sogabe Y; Matsumori T; Kakiuchi N; Tomono T; Mima A; Ueda T; Tsuda M; Yamauchi Y; Nishikawa Y; Sakuma Y; Ota Y; Maruno T; Uza N; Nagasawa T; Chiba T; Seno H
    Cancer Res; 2020 Oct; 80(19):4058-4070. PubMed ID: 32606001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma.
    Long KB; Tooker G; Tooker E; Luque SL; Lee JW; Pan X; Beatty GL
    Mol Cancer Ther; 2017 Sep; 16(9):1898-1908. PubMed ID: 28611107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1-Dependent Immune Evasion.
    Yang Y; Stang A; Schweickert PG; Lanman NA; Paul EN; Monia BP; Revenko AS; Palumbo JS; Mullins ES; Elzey BD; Janssen EM; Konieczny SF; Flick MJ
    Cancer Res; 2019 Jul; 79(13):3417-3430. PubMed ID: 31048498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma.
    Lastraioli E; Perrone G; Sette A; Fiore A; Crociani O; Manoli S; D'Amico M; Masselli M; Iorio J; Callea M; Borzomati D; Nappo G; Bartolozzi F; Santini D; Bencini L; Farsi M; Boni L; Di Costanzo F; Schwab A; Onetti Muda A; Coppola R; Arcangeli A
    Br J Cancer; 2015 Mar; 112(6):1076-87. PubMed ID: 25719829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment.
    Gomez-Chou SB; Swidnicka-Siergiejko AK; Badi N; Chavez-Tomar M; Lesinski GB; Bekaii-Saab T; Farren MR; Mace TA; Schmidt C; Liu Y; Deng D; Hwang RF; Zhou L; Moore T; Chatterjee D; Wang H; Leng X; Arlinghaus RB; Logsdon CD; Cruz-Monserrate Z
    Cancer Res; 2017 May; 77(10):2647-2660. PubMed ID: 28249896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1.
    Chen H; Li L; Hu J; Zhao Z; Ji L; Cheng C; Zhang G; Zhang T; Li Y; Chen H; Pan S; Sun B
    J Exp Clin Cancer Res; 2019 Jul; 38(1):297. PubMed ID: 31288830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of gemcitabine metabolizing enzymes and stromal components reveal complexities of preclinical pancreatic cancer models for therapeutic testing.
    Knoll L; Hamm J; Stroebel P; Jovan T; Goetze R; Singh S; Hessmann E; Ellenrieder V; Ammer-Herrmenau C; Neesse A
    Neoplasia; 2024 Jul; 53():101002. PubMed ID: 38744194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.